{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T14:44:44Z","timestamp":1789829084912,"version":"4.0.1"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T00:00:00Z","timestamp":1643846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T00:00:00Z","timestamp":1643846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA214960"],"award-info":[{"award-number":["R01CA214960"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA225701"],"award-info":[{"award-number":["R01CA225701"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA231471"],"award-info":[{"award-number":["R01CA231471"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s11912-022-01203-5","type":"journal-article","created":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T15:03:33Z","timestamp":1643900613000},"page":"285-294","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Immunotherapy Versus Hospice: Treatment Decision-Making in the Modern Era of Novel Cancer Therapies"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3889-5474","authenticated-orcid":false,"given":"Amy","family":"An","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,3]]},"reference":[{"key":"1203_CR1","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1472-684X-10-14","volume":"10","author":"AM Saito","year":"2011","unstructured":"Saito AM, et al. The effect on survival of continuing chemotherapy to near death. BMC Palliat Care. 2011;10:14.","journal-title":"BMC Palliat Care"},{"issue":"6","key":"1203_CR2","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1001\/jamaoncol.2015.2378","volume":"1","author":"HG Prigerson","year":"2015","unstructured":"Prigerson HG, et al. Chemotherapy use, performance status, and quality of life at the end of life. JAMA Oncol. 2015;1(6):778\u201384.","journal-title":"JAMA Oncol"},{"issue":"1","key":"1203_CR3","doi-asserted-by":"publisher","first-page":"e014661","DOI":"10.1136\/bmjopen-2016-014661","volume":"7","author":"T Reljic","year":"2017","unstructured":"Reljic T, et al. Treatment targeted at underlying disease versus palliative care in terminally ill patients: a systematic review. BMJ Open. 2017;7(1):e014661.","journal-title":"BMJ Open"},{"issue":"23","key":"1203_CR4","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1200\/JCO.2015.61.6706","volume":"33","author":"LE Schnipper","year":"2015","unstructured":"Schnipper LE, et al. American Society of Clinical Oncology Statement: a conceptual framework to assess the value of cancer treatment options. J Clin Oncol. 2015;33(23):2563\u201377.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1203_CR5","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1634\/theoncologist.2016-0419","volume":"22","author":"TF Nishijima","year":"2017","unstructured":"Nishijima TF, et al. Safety and tolerability of PD-1\/PD-L1 inhibitors compared with chemotherapy in patients with advanced cancer: a meta-analysis. Oncologist. 2017;22(4):470\u20139.","journal-title":"Oncologist"},{"issue":"13","key":"1203_CR6","doi-asserted-by":"publisher","first-page":"e25115","DOI":"10.1097\/MD.0000000000025115","volume":"100","author":"A Kapoor","year":"2021","unstructured":"Kapoor A, et al. Immune checkpoint inhibitors in patients with solid tumors and poor performance status: a prospective data from the real-world settings. Medicine (Baltimore). 2021;100(13):e25115.","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"1203_CR7","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s11912-018-0662-5","volume":"20","author":"DL Madden","year":"2018","unstructured":"Madden DL. From a patient advocate's perspective: does cancer immunotherapy represent a paradigm shift? Curr Oncol Rep. 2018;20(1):8.","journal-title":"Curr Oncol Rep"},{"issue":"2","key":"1203_CR8","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/jcph.591","volume":"56","author":"L Lee","year":"2016","unstructured":"Lee L, Gupta M, Sahasranaman S. Immune checkpoint inhibitors: an introduction to the next-generation cancer immunotherapy. J Clin Pharmacol. 2016;56(2):157\u201369.","journal-title":"J Clin Pharmacol"},{"key":"1203_CR9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.intimp.2018.06.001","volume":"62","author":"KM Hargadon","year":"2018","unstructured":"Hargadon KM, Johnson CE, Williams CJ. Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol. 2018;62:29\u201339.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"1203_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.19.02105","volume":"38","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 Study. J Clin Oncol. 2020;38(1):1\u201310.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1203_CR11","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","volume":"21","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21(10):1353\u201365.","journal-title":"Lancet Oncol"},{"issue":"4","key":"1203_CR12","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1177\/107327481502200415","volume":"22","author":"D Hui","year":"2015","unstructured":"Hui D. Prognostication of survival in patients with advanced cancer: predicting the unpredictable? Cancer Control. 2015;22(4):489\u201397.","journal-title":"Cancer Control"},{"issue":"10","key":"1203_CR13","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/s12032-018-1194-4","volume":"35","author":"M Bersanelli","year":"2018","unstructured":"Bersanelli M, et al. Patient performance status and cancer immunotherapy efficacy: a meta-analysis. Med Oncol. 2018;35(10):132.","journal-title":"Med Oncol"},{"key":"1203_CR14","doi-asserted-by":"crossref","unstructured":"Mencoboni M, et al. Effectiveness and safety of immune checkpoint inhibitors for patients with advanced non small-cell lung cancer in real-world: review and meta-analysis. Cancers (Basel). 2021; 13(6).","DOI":"10.3390\/cancers13061388"},{"issue":"8","key":"1203_CR15","doi-asserted-by":"publisher","first-page":"e2012534","DOI":"10.1001\/jamanetworkopen.2020.12534","volume":"3","author":"F Yang","year":"2020","unstructured":"Yang F, et al. Association of sex, age, and Eastern Cooperative Oncology Group Performance status with survival benefit of cancer immunotherapy in randomized clinical trials: a systematic review and meta-analysis. JAMA Netw Open. 2020;3(8):e2012534.","journal-title":"JAMA Netw Open"},{"issue":"9","key":"1203_CR16","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.jtho.2019.05.010","volume":"14","author":"DR Spigel","year":"2019","unstructured":"\u2022 Spigel DR, et al. Safety, efficacy, and patient-reported health-related quality of life and symptom burden with nivolumab in patients with advanced non-small cell lung cancer, including patients aged 70 years or older or with poor performance status (CheckMate 153). J Thorac Oncol. 2019;14(9):1628\u201339. Prospective trial including PS \u22652 patients.","journal-title":"J Thorac Oncol"},{"key":"1203_CR17","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.ejca.2019.11.019","volume":"127","author":"E Felip","year":"2020","unstructured":"\u2022 Felip E, et al. CheckMate 171: a phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations. Eur J Cancer. 2020;127:160\u201372. Prospective trial including PS \u22652 and geriatric patients.","journal-title":"Eur J Cancer"},{"key":"1203_CR18","doi-asserted-by":"publisher","first-page":"S214","DOI":"10.1016\/j.jtho.2019.08.424","volume":"14","author":"F Barlesi","year":"2019","unstructured":"Barlesi F, et al. OA04.02 CheckMate 817: first-line nivolumab + ipilimumab in patients with ECOG PS 2 and other special populations with advanced NSCLC. J Thorac Oncol. 2019;14:S214\u20135.","journal-title":"J Thorac Oncol"},{"issue":"9","key":"1203_CR19","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/S2213-2600(20)30033-3","volume":"8","author":"G Middleton","year":"2020","unstructured":"\u2022 Middleton G, et al. Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial. Lancet Respir Med. 2020;8(9):895\u2013904. Prospective trial using immunotherapy in lung cancer for patients with PS 2.","journal-title":"Lancet Respir Med"},{"key":"1203_CR20","doi-asserted-by":"crossref","unstructured":"\u2022 Ardizzoni A, et al. Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer. J Immunother Cancer. 2021; 9(3). Prostpective trial including PS \u22652 patients.","DOI":"10.1136\/jitc-2020-001865"},{"issue":"1","key":"1203_CR21","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/onco.13561","volume":"26","author":"SM Durbin","year":"2021","unstructured":"\u2022 Durbin SM, et al. Clinical outcomes of patients with metastatic cancer receiving immune checkpoint inhibitors in the inpatient setting. Oncologist. 2021;26(1):49\u201355. This study describes outcomes of patients receiving immunotherapy in a hospitalized setting.","journal-title":"Oncologist"},{"key":"1203_CR22","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ejca.2020.02.023","volume":"130","author":"F Facchinetti","year":"2020","unstructured":"Facchinetti F, et al. First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status. Eur J Cancer. 2020;130:155\u201367.","journal-title":"Eur J Cancer"},{"key":"1203_CR23","doi-asserted-by":"crossref","unstructured":"Gounant V, et al. Does very poor performance status systematically preclude single agent anti-PD-1 immunotherapy? A multicenter study of 35 consecutive patients. Cancers (Basel). 2021. 13(5).","DOI":"10.3390\/cancers13051040"},{"key":"1203_CR24","doi-asserted-by":"crossref","unstructured":"Greally M, Chou JF, Chatila WK, Margolis M, Capanu M, Hechtman JF, et al. Clinical and molecular predictors of response to immune checkpoint inhibitors in patients with advanced esophagogastric cancer. Clin Cancer Res. 2019;25(20):6160\u20139.","DOI":"10.1158\/1078-0432.CCR-18-3603"},{"issue":"2","key":"1203_CR25","doi-asserted-by":"publisher","first-page":"e2037120","DOI":"10.1001\/jamanetworkopen.2020.37120","volume":"4","author":"K Sehgal","year":"2021","unstructured":"Sehgal K, et al. Association of performance status with survival in patients with advanced non-small cell lung cancer treated with pembrolizumab monotherapy. JAMA Netw Open. 2021;4(2):e2037120.","journal-title":"JAMA Netw Open"},{"issue":"6","key":"1203_CR26","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1111\/ajco.12702","volume":"13","author":"A Wong","year":"2017","unstructured":"Wong A, et al. Clinical and palliative care outcomes for patients of poor performance status treated with antiprogrammed death-1 monoclonal antibodies for advanced melanoma. Asia Pac J Clin Oncol. 2017;13(6):385\u201390.","journal-title":"Asia Pac J Clin Oncol"},{"key":"1203_CR27","doi-asserted-by":"crossref","unstructured":"Popovic G, et al. Patient-reported functional status in outpatients with advanced cancer: correlation with physician-reported scores and survival. J Pain Symptom Manag. 2018.","DOI":"10.1016\/j.jpainsymman.2018.02.015"},{"issue":"1","key":"1203_CR28","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.annonc.2019.10.008","volume":"31","author":"DE Magee","year":"2020","unstructured":"Magee DE, et al. Adverse event profile for immunotherapy agents compared with chemotherapy in solid organ tumors: a systematic review and meta-analysis of randomized clinical trials. Ann Oncol. 2020;31(1):50\u201360.","journal-title":"Ann Oncol"},{"issue":"12","key":"1203_CR29","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","volume":"26","author":"J Naidoo","year":"2015","unstructured":"Naidoo J, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2015;26(12):2375\u201391.","journal-title":"Ann Oncol"},{"issue":"5","key":"1203_CR30","doi-asserted-by":"publisher","first-page":"3259","DOI":"10.3390\/curroncol28050283","volume":"28","author":"A Paderi","year":"2021","unstructured":"Paderi A, et al. Safety of immune checkpoint inhibitors in elderly patients: an observational study. Curr Oncol. 2021;28(5):3259\u201367.","journal-title":"Curr Oncol"},{"issue":"12","key":"1203_CR31","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang DY, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4(12):1721\u20138.","journal-title":"JAMA Oncol"},{"issue":"6","key":"1203_CR32","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1007\/s10637-019-00736-0","volume":"37","author":"DJ Martini","year":"2019","unstructured":"\u2022 Martini DJ, et al. Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials. Investig New Drugs. 2019;37(6):1198\u2013206. This study reports on outcomes of patients retreated with immunotherapy on phase 1 trials after prior immunotherapy failure.","journal-title":"Investig New Drugs"},{"issue":"10","key":"1203_CR33","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1001\/jamaoncol.2020.3524","volume":"6","author":"SM Tolaney","year":"2020","unstructured":"Tolaney SM, et al. Effect of eribulin with or without pembrolizumab on progression-free survival for patients with hormone receptor-positive, ERBB2-negative metastatic breast cancer: a randomized clinical trial. JAMA Oncol. 2020;6(10):1598\u2013605.","journal-title":"JAMA Oncol"},{"key":"1203_CR34","doi-asserted-by":"crossref","unstructured":"Naing A, et al. A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors. J Immunother Cancer. 2020; 8(1).","DOI":"10.1136\/jitc-2020-000530"},{"issue":"4","key":"1203_CR35","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1002\/cam4.3630","volume":"10","author":"MR Patel","year":"2021","unstructured":"Patel MR, et al. A phase 2 trial of trifluridine\/tipiracil plus nivolumab in patients with heavily pretreated microsatellite-stable metastatic colorectal cancer. Cancer Med. 2021;10(4):1183\u201390.","journal-title":"Cancer Med"},{"issue":"2","key":"1203_CR36","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.3747\/co.26.4377","volume":"26","author":"C Roesel","year":"2019","unstructured":"Roesel C, et al. Lazarus-type tumour response to therapy with nivolumab for sarcomatoid carcinomas of the lung. Curr Oncol. 2019;26(2):e270\u20133.","journal-title":"Curr Oncol"},{"issue":"4","key":"1203_CR37","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1111\/1759-7714.13793","volume":"12","author":"I Shaforostova","year":"2021","unstructured":"Shaforostova I, et al. To treat or not to treat: A rare case of response to pembrolizumab-based immunotherapy-chemotherapy in non-small cell lung cancer with acute liver failure due to multiple bile duct metastases. Thorac Cancer. 2021;12(4):553\u20136.","journal-title":"Thorac Cancer"},{"issue":"6","key":"1203_CR38","doi-asserted-by":"publisher","first-page":"4384","DOI":"10.21037\/apm-20-2096","volume":"9","author":"Y Wang","year":"2020","unstructured":"Wang Y, et al. Nivolumab in combination with anlotinib achieved remarkable efficacy in a patient with driver-negative lung squamous cell carcinoma and PS of 4. Ann Palliat Med. 2020;9(6):4384\u20138.","journal-title":"Ann Palliat Med"},{"issue":"1","key":"1203_CR39","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1186\/s12885-019-6073-7","volume":"19","author":"MA Bilen","year":"2019","unstructured":"Bilen MA, et al. Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy. BMC Cancer. 2019;19(1):857.","journal-title":"BMC Cancer"},{"key":"1203_CR40","doi-asserted-by":"crossref","unstructured":"Zamarin D, et al. Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial. J Immunother Cancer 2020; 8(1).","DOI":"10.1136\/jitc-2020-000829"},{"issue":"1","key":"1203_CR41","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1186\/s12885-019-6287-8","volume":"19","author":"Z Liu","year":"2019","unstructured":"Liu Z, et al. Complete response to the combination of Lenvatinib and Pembrolizumab in an advanced hepatocellular carcinoma patient: a case report. BMC Cancer. 2019;19(1):1062.","journal-title":"BMC Cancer"},{"issue":"1","key":"1203_CR42","doi-asserted-by":"publisher","first-page":"210","DOI":"10.21037\/apm-20-2279","volume":"10","author":"NF Nie","year":"2021","unstructured":"Nie NF, et al. Lazarus type response to immunotherapy in three patients with poor performance status and locally advanced NSCLC: a case series and literature review. Ann Palliat Med. 2021;10(1):210\u20139.","journal-title":"Ann Palliat Med"},{"key":"1203_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2021.03.022","volume":"156","author":"T Nakasuka","year":"2021","unstructured":"Nakasuka T, et al. A case of dramatic reduction in cancer-associated thrombus following initiation of pembrolizumab in patient with a poor performance status and PD-L1(+) lung adenocarcinoma harboring CCDC6-RET fusion gene and NF1\/TP53 mutations. Lung Cancer. 2021;156:1\u20134.","journal-title":"Lung Cancer"},{"key":"1203_CR44","doi-asserted-by":"publisher","first-page":"867","DOI":"10.2147\/OTT.S229813","volume":"13","author":"A Petrillo","year":"2020","unstructured":"Petrillo A, et al. Nivolumab in heavily pretreated metastatic gastric cancer patients: real-life data from a Western population. Onco Targets Ther. 2020;13:867\u201376.","journal-title":"Onco Targets Ther"},{"issue":"9","key":"1203_CR45","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1634\/theoncologist.2020-0014","volume":"25","author":"F Pietrantonio","year":"2020","unstructured":"Pietrantonio F, et al. Efficacy and safety of immune checkpoint inhibitors in patients with microsatellite instability-high end-stage cancers and poor performance status related to high disease burden. Oncologist. 2020;25(9):803\u20139.","journal-title":"Oncologist"},{"issue":"8","key":"1203_CR46","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","volume":"36","author":"MJ Overman","year":"2018","unstructured":"Overman MJ, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient\/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol. 2018;36(8):773\u20139.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1203_CR47","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","volume":"51","author":"RM Samstein","year":"2019","unstructured":"Samstein RM, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51(2):202\u20136.","journal-title":"Nat Genet"},{"issue":"25","key":"1203_CR48","doi-asserted-by":"publisher","first-page":"4013","DOI":"10.1200\/JCO.2010.29.5618","volume":"28","author":"E Bruera","year":"2010","unstructured":"Bruera E, Hui D. Integrating supportive and palliative care in the trajectory of cancer: establishing goals and models of care. J Clin Oncol. 2010;28(25):4013\u20137.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1203_CR49","doi-asserted-by":"publisher","first-page":"e828","DOI":"10.1200\/JOP.2016.010686","volume":"12","author":"KE Bickel","year":"2016","unstructured":"Bickel KE, et al. Defining high-quality palliative care in oncology practice: an American Society of Clinical Oncology\/American Academy of Hospice and Palliative Medicine Guidance Statement. J Oncol Pract. 2016;12(9):e828\u201338.","journal-title":"J Oncol Pract"},{"issue":"8","key":"1203_CR50","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1056\/NEJMoa1000678","volume":"363","author":"JS Temel","year":"2010","unstructured":"\u2022\u2022 Temel JS, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363(8):733\u201342. Landmark trial establishing the benefits of concurrent palliative care.","journal-title":"N Engl J Med"},{"issue":"14","key":"1203_CR51","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1001\/jama.299.14.1698","volume":"299","author":"C Zimmermann","year":"2008","unstructured":"Zimmermann C, et al. Effectiveness of specialized palliative care: a systematic review. Jama. 2008;299(14):1698\u2013709.","journal-title":"Jama"},{"issue":"1","key":"1203_CR52","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1200\/JCO.2016.70.1474","volume":"35","author":"BR Ferrell","year":"2017","unstructured":"Ferrell BR, et al. Integration of palliative care into standard oncology care: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2017;35(1):96\u2013112.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1203_CR53","doi-asserted-by":"publisher","first-page":"989","DOI":"10.6004\/jnccn.2017.0132","volume":"15","author":"M Dans","year":"2017","unstructured":"Dans M, et al. NCCN guidelines insights: palliative care, Version 2.2017. J Natl Compr Cancer Netw. 2017;15(8):989\u201397.","journal-title":"J Natl Compr Cancer Netw"},{"issue":"8","key":"1203_CR54","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1200\/JCO.2011.38.5161","volume":"30","author":"TJ Smith","year":"2012","unstructured":"Smith TJ, et al. American Society of Clinical Oncology provisional clinical opinion: the integration of palliative care into standard oncology care. J Clin Oncol. 2012;30(8):880\u20137.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1203_CR55","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/nrclinonc.2015.201","volume":"13","author":"D Hui","year":"2016","unstructured":"Hui D, Bruera E. Integrating palliative care into the trajectory of cancer care. Nat Rev Clin Oncol. 2016;13(3):159\u201371.","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"1203_CR56","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s11864-016-0397-1","volume":"17","author":"D Chandrasekar","year":"2016","unstructured":"Chandrasekar D, Tribett E, Ramchandran K. Integrated palliative care and oncologic care in non-small-cell lung cancer. Curr Treat Options in Oncol. 2016;17(5):23.","journal-title":"Curr Treat Options in Oncol"},{"key":"1203_CR57","doi-asserted-by":"crossref","unstructured":"Collins A, et al. Transition points for the routine integration of palliative care in patients with advanced cancer. J Pain Symptom Manag. 2018.","DOI":"10.1016\/j.jpainsymman.2018.03.022"},{"issue":"13","key":"1203_CR58","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1200\/JCO.2014.58.6362","volume":"33","author":"MA Bakitas","year":"2015","unstructured":"Bakitas MA, et al. Early versus delayed initiation of concurrent palliative oncology care: patient outcomes in the ENABLE III randomized controlled trial. J Clin Oncol. 2015;33(13):1438\u201345.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1203_CR59","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1200\/JCO.2017.75.6676","volume":"36","author":"M Hoerger","year":"2018","unstructured":"Hoerger M, et al. Defining the elements of early palliative care that are associated with patient-reported outcomes and the delivery of end-of-life care. J Clin Oncol. 2018;36(11):1096\u2013102.","journal-title":"J Clin Oncol"},{"issue":"20","key":"1203_CR60","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1200\/JCO.2014.60.3274","volume":"33","author":"D Hui","year":"2015","unstructured":"Hui D, et al. Palliative oncologists: specialists in the science and art of patient care. J Clin Oncol. 2015;33(20):2314\u20137.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1203_CR61","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1634\/theoncologist.2016-0277","volume":"22","author":"S Dalal","year":"2017","unstructured":"Dalal S, Bruera E. End-of-life care matters: palliative cancer care results in better care and lower costs. Oncologist. 2017;22(4):361\u20138.","journal-title":"Oncologist"},{"issue":"1","key":"1203_CR62","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s40425-019-0557-5","volume":"7","author":"CD Bergerot","year":"2019","unstructured":"Bergerot CD, et al. Perception of cure among patients with metastatic genitourinary cancer initiating immunotherapy. J Immunother Cancer. 2019;7(1):71.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"1203_CR63","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jpainsymman.2018.09.014","volume":"57","author":"J DeMartini","year":"2019","unstructured":"DeMartini J, et al. Patients' hopes for advanced cancer treatment. J Pain Symptom Manag. 2019;57(1):57\u201363.e2.","journal-title":"J Pain Symptom Manag"},{"key":"1203_CR64","doi-asserted-by":"crossref","unstructured":"Temel JS, Shaw AT, Greer JA. Challenge of prognostic uncertainty in the modern era of cancer therapeutics. J Clin Oncol. 2016.","DOI":"10.1200\/JCO.2016.67.8573"},{"key":"1203_CR65","doi-asserted-by":"publisher","first-page":"e110","DOI":"10.1200\/EDBK_238795","volume":"39","author":"R Elias","year":"2019","unstructured":"Elias R, Odejide O. Immunotherapy in older adults: a checkpoint to palliation? Am Soc Clin Oncol Educ Book. 2019;39:e110\u201320.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"5","key":"1203_CR66","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1007\/s00520-018-4443-3","volume":"27","author":"D Levy","year":"2019","unstructured":"Levy D, et al. Certainty within uncertainty: a qualitative study of the experience of metastatic melanoma patients undergoing pembrolizumab immunotherapy. Support Care Cancer. 2019;27(5):1845\u201352.","journal-title":"Support Care Cancer"},{"issue":"2","key":"1203_CR67","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s11864-020-00810-3","volume":"22","author":"D Hui","year":"2021","unstructured":"Hui D, Mo L, Paiva CE. The importance of prognostication: impact of prognostic predictions, disclosures, awareness, and acceptance on patient outcomes. Curr Treat Options in Oncol. 2021;22(2):12.","journal-title":"Curr Treat Options in Oncol"},{"issue":"4","key":"1203_CR68","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1097\/SPC.0000000000000459","volume":"13","author":"D Hui","year":"2019","unstructured":"Hui D, Maxwell JP, Paiva CE. Dealing with prognostic uncertainty: the role of prognostic models and websites for patients with advanced cancer. Curr Opin Support Palliat Care. 2019;13(4):360\u20138.","journal-title":"Curr Opin Support Palliat Care"},{"issue":"9","key":"1203_CR69","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1200\/JCO.2010.30.7173","volume":"29","author":"H Seow","year":"2011","unstructured":"Seow H, et al. Trajectory of performance status and symptom scores for patients with cancer during the last six months of life. J Clin Oncol. 2011;29(9):1151\u20138.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1203_CR70","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1200\/JCO.2009.25.4672","volume":"28","author":"JW Mack","year":"2010","unstructured":"Mack JW, et al. End-of-life discussions, goal attainment, and distress at the end of life: predictors and outcomes of receipt of care consistent with preferences. J Clin Oncol. 2010;28(7):1203\u20138.","journal-title":"J Clin Oncol"},{"issue":"14","key":"1203_CR71","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1001\/jama.300.14.1665","volume":"300","author":"AA Wright","year":"2008","unstructured":"Wright AA, et al. Associations between end-of-life discussions, patient mental health, medical care near death, and caregiver bereavement adjustment. Jama. 2008;300(14):1665\u201373.","journal-title":"Jama"},{"issue":"10","key":"1203_CR72","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1177\/1049909119848148","volume":"36","author":"LT Starr","year":"2019","unstructured":"Starr LT, et al. Associations among end-of-life discussions, health-care utilization, and costs in persons with advanced cancer: a systematic review. Am J Hosp Palliat Care. 2019;36(10):913\u201326.","journal-title":"Am J Hosp Palliat Care"},{"issue":"35","key":"1203_CR73","doi-asserted-by":"publisher","first-page":"4387","DOI":"10.1200\/JCO.2012.43.6055","volume":"30","author":"JW Mack","year":"2012","unstructured":"Mack JW, et al. Associations between end-of-life discussion characteristics and care received near death: a prospective cohort study. J Clin Oncol. 2012;30(35):4387\u201395.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1203_CR74","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/jso.25623","volume":"120","author":"AZ Paredes","year":"2019","unstructured":"Paredes AZ, et al. Hospice utilization among Medicare beneficiaries dying from pancreatic cancer. J Surg Oncol. 2019;120(4):624\u201331.","journal-title":"J Surg Oncol"},{"issue":"10","key":"1203_CR75","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1089\/jpm.2013.0164","volume":"16","author":"ET Loggers","year":"2013","unstructured":"Loggers ET, et al. Predictors of intensive end-of-life and hospice care in Latino and white advanced cancer patients. J Palliat Med. 2013;16(10):1249\u201354.","journal-title":"J Palliat Med"},{"issue":"1","key":"1203_CR76","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jpainsymman.2019.04.006","volume":"58","author":"YE Turkman","year":"2019","unstructured":"Turkman YE, et al. Disparities in hospice utilization for older cancer patients living in the Deep South. J Pain Symptom Manag. 2019;58(1):86\u201391.","journal-title":"J Pain Symptom Manag"},{"key":"1203_CR77","doi-asserted-by":"crossref","unstructured":"Chen Y, et al. Cost and utilization of lung cancer end-of-life care among racial-ethnic minority groups in the United States. Oncologist. 2019.","DOI":"10.1634\/theoncologist.2019-0303"},{"issue":"11","key":"1203_CR78","doi-asserted-by":"publisher","first-page":"e1355","DOI":"10.1200\/OP.20.00010","volume":"16","author":"F Riaz","year":"2020","unstructured":"Riaz F, et al. Adoption of immune checkpoint inhibitors and patterns of care at the end of life. JCO Oncol Pract. 2020;16(11):e1355\u201370.","journal-title":"JCO Oncol Pract"},{"issue":"6","key":"1203_CR79","doi-asserted-by":"publisher","first-page":"e397","DOI":"10.1634\/theoncologist.2019-0039","volume":"24","author":"RB Parikh","year":"2019","unstructured":"Parikh RB, et al. Trends in checkpoint inhibitor therapy for advanced urothelial cell carcinoma at the end of life: insights from real-world practice. Oncologist. 2019;24(6):e397\u20139.","journal-title":"Oncologist"},{"issue":"10","key":"1203_CR80","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1002\/cncr.32782","volume":"126","author":"LA Petrillo","year":"2020","unstructured":"Petrillo LA, et al. Performance status and end-of-life care among adults with non-small cell lung cancer receiving immune checkpoint inhibitors. Cancer. 2020;126(10):2288\u201395.","journal-title":"Cancer"},{"issue":"7","key":"1203_CR81","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1089\/jpm.2019.0383","volume":"23","author":"C Glisch","year":"2020","unstructured":"Glisch C, et al. Immune checkpoint inhibitor use near the end of life: a single-center retrospective study. J Palliat Med. 2020;23(7):977\u20139.","journal-title":"J Palliat Med"},{"issue":"12","key":"1203_CR82","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1200\/OP.20.00309","volume":"16","author":"MN Patel","year":"2020","unstructured":"Patel MN, et al. Hospice use among patients with cancer: trends, barriers, and future directions. JCO Oncol Pract. 2020;16(12):803\u20139.","journal-title":"JCO Oncol Pract"},{"key":"1203_CR83","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.2147\/PPA.S248295","volume":"14","author":"B Hauber","year":"2020","unstructured":"\u2022 Hauber B, et al. The value of hope: patients' and physicians' preferences for survival in advanced non-small cell lung cancer. Patient Prefer Adherence. 2020;14:2093\u2013104. This study describes differences in priorities and considerations when patients consider treatment options like immunotherapy compared to physicians.","journal-title":"Patient Prefer Adherence"},{"issue":"11","key":"1203_CR84","doi-asserted-by":"publisher","first-page":"e1190","DOI":"10.1634\/theoncologist.2018-0820","volume":"24","author":"A Wong","year":"2019","unstructured":"Wong A, Billett A, Milne D. Balancing the hype with reality: what do patients with advanced melanoma consider when making the decision to have immunotherapy? Oncologist. 2019;24(11):e1190\u20136.","journal-title":"Oncologist"},{"issue":"1","key":"1203_CR85","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/s12967-021-02937-9","volume":"19","author":"D Santini","year":"2021","unstructured":"Santini D, et al. PD-1\/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort. J Transl Med. 2021;19(1):270.","journal-title":"J Transl Med"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-022-01203-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-022-01203-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-022-01203-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T22:22:20Z","timestamp":1700173340000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-022-01203-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,3]]},"references-count":85,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["1203"],"URL":"https:\/\/doi.org\/10.1007\/s11912-022-01203-5","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,3]]},"assertion":[{"value":"28 September 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}